Does inhaled nitric oxide treatment of pulmonary hypertension in extremely premature infants improve patient outcomes?

Puntos clave

• This research aims to evaluate if inhaled nitric oxide treatment reduces the risk of death and bronchopulmonary dysplasia in extremely preterm infants with pulmonary hypertension.
• Conducted a single-center double-blinded randomized control trial
• Included infants born at or before 29 weeks' gestation
• Patients were eligible if they received positive pressure ventilation at 72 postnatal hours
• Treatment with inhaled nitric oxide showed a potential reduction in death risk
• There was also a decrease in the incidence of bronchopulmonary dysplasia among treated infants.